ALIA-1758 vs Lecanemab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Alzheimer's Disease
Shared mechanism: Amyloid-beta (monoclonal antibody) · full Alzheimer's Disease pipeline
ALIA-1758
Developed by AbbVie
NCT06406348 · Phase 1 · completed
The trial was randomized and blinded against placebo, but it was conducted in healthy volunteers purely to check safety and dosing rather than cognitive or disease benefit, and no results have been posted yet.
No aligned efficacy figure on record for this race.
Lecanemab · Leqembi
Marketed by Eisai and partners
NCT01767311 · Phase 2 · completed
Randomized, triple-masked phase 2b in early Alzheimer's disease (856 participants). The Bayesian primary analysis of the ADCOMS composite at 12 months estimated a 63.8% posterior probability of meaningful benefit for the highest dose, short of the study's prespecified success criterion, so the primary endpoint was not met.
Next expected readout: December 2026 · NCT06602258 (registry estimate)
Reported efficacy
Core Study Phase: Change From Baseline in Alzheimer's Disease Composite Score (ADCOMS) at Month 12 (Core Study Phase: at Month 12); Core Study Phase: Number of Participants With All Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) (From first dose of the study drug (Week 1) up to 90 days after last dose of study drug (up to 21 months)); OLE Phase: Number of Participants With All TEAEs and SAEs (From first dose of the study drug (Week 1) up to 30 days after last dose of study drug (up to 61 months)): ADCOMS change from baseline at Month 12 (lower = less decline): lecanemab 10 mg/kg biweekly 0.077 and 10 mg/kg monthly 0.084 vs placebo 0.113; lower doses did not separate: 2.5 mg/kg biweekly 0.134, 5 mg/kg monthly 0.119, 5 mg/kg biweekly 0.116. (missed)
Result source: NCT01767311
Results for Alzheimer's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | ALIA-1758 | Lecanemab |
|---|---|---|
| CDR-SB, change | —Not reported | 1.2 vs 1.5−0.3 vs placeboNCT017673119 other results
|
| ADAS-Cog11, change | —Not reported | —Trial running · NCT01760005 |
| ADCS-ADL, change | —Not reported | —Trial running · NCT01760005 |
| MMSE, change | —Not reported | —Trial running · NCT01760005 |
| Amyloid PET, change (centiloids) | —Not reported | —Trial running · NCT01760005 |
CDR-SB, change
- ALIA-1758
- —Not reported
- Lecanemab
- 1.2 vs 1.5−0.3 vs placeboNCT01767311
9 other results
- 1.1 vs 1.5 NCT01767311
- 0.7 vs 0.9 NCT01767311
- 0.6 vs 0.9 NCT01767311
- 1.7 vs 1.5 NCT01767311
- 1.5 vs 1.5 NCT01767311
- 1.3 vs 0.9 NCT01767311
- 0.9 vs 0.9 NCT01767311
- 1.2 vs 1.5 NCT01767311
- 1.0 vs 0.9 NCT01767311
ADAS-Cog11, change
- ALIA-1758
- —Not reported
- Lecanemab
- —Trial running · NCT01760005
ADCS-ADL, change
- ALIA-1758
- —Not reported
- Lecanemab
- —Trial running · NCT01760005
MMSE, change
- ALIA-1758
- —Not reported
- Lecanemab
- —Trial running · NCT01760005
Amyloid PET, change (centiloids)
- ALIA-1758
- —Not reported
- Lecanemab
- —Trial running · NCT01760005
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
ALIA-1758: no structured comparison results are available for Alzheimer's Disease.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. ALIA-1758: 0 of 4 rows · Lecanemab: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Lecanemab |
|---|---|
| Dropout rate | 46%10 mg/kg Biweeklya NCT01767311 · Phase 2 show 5 more results38.7%10 mg/kg Monthly NCT01767311 · Phase 2 —10 mg/kg Biweekly NCT01767311 · Phase 2 33.7%5 mg/kg Biweekly NCT01767311 · Phase 2 27.5%5 mg/kg Monthly NCT01767311 · Phase 2 32.7%2.5 mg/kg Biweekly NCT01767311 · Phase 2 |
| Discontinued due to AEs | 7.5%10 mg/kg Biweeklya NCT01767311 · Phase 2 show 5 more results9.1%10 mg/kg Monthly NCT01767311 · Phase 2 —10 mg/kg Biweekly NCT01767311 · Phase 2 5.4%5 mg/kg Biweekly NCT01767311 · Phase 2 3.9%5 mg/kg Monthly NCT01767311 · Phase 2 7.7%2.5 mg/kg Biweekly NCT01767311 · Phase 2 |
| Serious AEs | 15.5%10 mg/kg Biweeklya NCT01767311 · Phase 2 show 5 more results12.3%10 mg/kg Monthly NCT01767311 · Phase 2 33.3%10 mg/kg Biweekly NCT01767311 · Phase 2 17.4%5 mg/kg Biweekly NCT01767311 · Phase 2 7.8%5 mg/kg Monthly NCT01767311 · Phase 2 19.2%2.5 mg/kg Biweekly NCT01767311 · Phase 2 |
| Most frequent reported AEs | 10 mg/kg Biweeklya infusion related reaction 19.3% (placebo 3.3%) headache 14.3% (placebo 10.2%) upper respiratory tract infection 11.8% (placebo 16.7%) NCT01767311 · Phase 2 show 5 more results10 mg/kg Monthly infusion related reaction 23.3% (placebo 3.3%) headache 17% (placebo 10.2%) urinary tract infection 9.9% (placebo 13.1%) NCT01767311 · Phase 2 10 mg/kg Biweekly fall 26.1% (placebo 11.4%) infusion related reaction 21.7% (placebo 3.3%) urinary tract infection 18.9% (placebo 13.1%) NCT01767311 · Phase 2 5 mg/kg Biweekly headache 18.5% (placebo 10.2%) urinary tract infection 18.5% (placebo 13.1%) fall 14.1% (placebo 11.4%) NCT01767311 · Phase 2 5 mg/kg Monthly cerebral microhaemorrhage 13.7% (placebo 4.9%) diarrhoea 13.7% (placebo 4.9%) nasopharyngitis 13.7% (placebo 11.4%) NCT01767311 · Phase 2 2.5 mg/kg Biweekly headache 17.3% (placebo 10.2%) upper respiratory tract infection 13.5% (placebo 16.7%) diarrhoea 9.6% (placebo 4.9%) NCT01767311 · Phase 2 |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Lecanemab
show 9 more results
show 9 more results
show 9 more results
show 9 more results
show 17 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ALIA-1758's landscape · Lecanemab's landscape